Lindsey Hoffman
Pediatric Hematology-Oncology · Aurora, CONPI 1366746893
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,847 of the $12,041 with a category attached, or 98.4%. 7 manufacturers reported payments, led by AstraZeneca at 37.1% of the total. Reporting peaked in 2023 at $5,507 and has fallen 64.7% since, to $1,943 in 2024.
Across 9 payments — averaging $1337.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Eli Lilly$4K
- Novartis$2K
- Bayer$1K
- Portola Pharmaceuticals, LLC$126
- Jazz Pharmaceuticals Inc.$25
- plus $19 from 1 others
Across 47 payments — averaging $225,528 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10.5M
- Blueprint Medicines Corporation$70K
- Eli Lilly$62K
What the payments were for
- Consulting fees$11,84798%
- Food & beverage$1942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $4,465 |
| Eli Lilly | 1 | $4,375 |
| Novartis | 2 | $1,900 |
| Bayer | 1 | $1,132 |
| Portola Pharmaceuticals, LLC | 1 | $126 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Incyte Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,041 in reported general payments places this provider in the 75th percentile of 60 pediatric hematology-oncology providers in Colorado.
See all pediatric hematology-oncology providers in Colorado →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TafinlarDabrafenib Mesylate | 13 | $219,789 |
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $210,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTafinlar, Mekinist | $1,900 | $430,12726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 60 pediatric hematology-oncology providers in Colorado.
Other pediatric hematology-oncology in Aurora
- Michael WangAurora$225K
- Lia GoreAurora$68K
- Marilyn Manco JohnsonAurora$67K
- Michael VernerisAurora$60K
- Christopher McKinneyAurora$32K
- Daniel AmbrusoAurora$30K
- Taizo NakanoAurora$24K
- Hesham EissaAurora$23K
- Rachelle NussAurora$23K
- Terry FryAurora$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.